Get the Stockscreener App
7.35
1.52%
0.11
Pre-market:
7.34
-0.010
-0.14%
Certara Inc stock is traded at $7.35, with a volume of 4.79M.
It is up +1.52% in the last 24 hours and down -3.42% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
See More
Previous Close:
$7.24
Open:
$7.28
24h Volume:
4.79M
Relative Volume:
1.95
Market Cap:
$1.17B
Revenue:
$405.76M
Net Income/Loss:
$7.98M
P/E Ratio:
147.00
EPS:
0.05
Net Cash Flow:
$77.47M
1W Performance:
+11.53%
1M Performance:
-3.42%
6M Performance:
-30.53%
1Y Performance:
-37.97%
1-Day Range:
$7.24
$7.475
1-Week Range:
$6.04
$7.475
52-Week Range:
$6.04
$15.38
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
7.35 | 1.15B | 405.76M | 7.98M | 77.47M | 0.05 |
|
VEEV
Veeva Systems Inc
|
188.48 | 30.56B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
51.29 | 9.19B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.96 | 7.33B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
81.15 | 6.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.93 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-21-25 | Initiated | Rothschild & Co Redburn | Buy |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-29-25 | Initiated | Craig Hallum | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-08-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Certara (CERT) Gains FDA Acceptance for PBPK Modeling in Drug Ap - GuruFocus
Certara, Inc. (CERT) Stock Analysis: Exploring a 38% Potential Upside in Health Information Services - DirectorsTalk Interviews
CERT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Certara Simcyp® simulator results replace ten human trials for chronic myeloid leukemia (CML) therapy asciminib - marketscreener.com
Certara Simcyp Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - Bitget
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - The Manila Times
FDA accepts virtual-patient data so leukemia drug avoids 10 trials - Stock Titan
Certara, Inc. $CERT Stock Holdings Boosted by Roubaix Capital LLC - MarketBeat
Certara Earnings Call: Software Strength Amid Transition - The Globe and Mail
Certara (CERT) director granted 5,547 restricted stock units - Stock Titan
Certara (CERT) director Arjun Bedi submits initial Form 3 insider filing - Stock Titan
Certara (CERT) Is Up 9.6% After Calling 2026 a Transition Year With Slower Growth Guidance - Sahm
Discipline and Rules-Based Execution in CERT Response - Stock Traders Daily
Certara, Inc. Hits 52-Week Low at USD 6.04 Amid Market Struggles - Markets Mojo
Certara (NASDAQ:CERT) Trading 6.1% HigherHere's What Happened - MarketBeat
Certara (CERT) Faces Downgrade Amid Strategic Uncertainty - GuruFocus
Certara (NASDAQ:CERT) Given New $8.00 Price Target at Barclays - MarketBeat
Certara stock downgraded at Craig-Hallum on growth concerns By Investing.com - Investing.com Canada
Certara stock downgraded at Craig-Hallum on growth concerns - Investing.com
Certara (NASDAQ:CERT) Rating Lowered to "Hold" at Craig Hallum - MarketBeat
Drug development firm Certara lines up three March investor talks - Stock Titan
Morgan Stanley Cuts Price Target on Certara to $11 From $12, Keeps Equalweight Rating - marketscreener.com
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara Q4 2025 slides: services growth offsets software weakness By Investing.com - Investing.com Australia
Certara stock hits 52-week low at 6.26 USD By Investing.com - Investing.com Australia
Certara (NASDAQ:CERT) Issues Earnings Results - MarketBeat
Leerink Maintains Outperform on Certara, Inc. (CERT) Feb 26 2026 PT $10 - Meyka
Certara to Participate in Upcoming Investor Conferences - Bitget
Certara Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TD Cowen cuts Certara stock price target on macro headwinds - Investing.com
TD Cowen cuts Certara stock price target on macro headwinds By Investing.com - Investing.com South Africa
Leerink cuts Certara stock price target on weak bookings, guidance By Investing.com - Investing.com South Africa
Certara outlines flat to 4% 2026 revenue growth as new CEO signals operational overhaul and $10M cost avoidance - MSN
Leerink cuts Certara stock price target on weak bookings, guidance - Investing.com
Certara Q4 2025 slides: services growth offsets software weakness - Investing.com
Certara Q4 Earnings Call Highlights - Yahoo Finance
CERT: 2026 guidance targets flat to 4% revenue growth amid operational changes and AI-driven focus - TradingView
Earnings call transcript: Certara Q4 2025 reports mixed results - Investing.com
Earnings call transcript: Certara Q4 2025 reports mixed results By Investing.com - Investing.com Australia
Certara (NASDAQ:CERT) Sets New 52-Week Low on Disappointing Earnings - MarketBeat
CERT: 2025 revenue grew 9%, but 2026 guidance is flat to 4% amid operational and market shifts - TradingView
Certara stock hits 52-week low at 6.26 USD - Investing.com
Certara, Inc. (CERT) Q4 Results Fall Short of Expectations - Bitget
Certara earnings on deck: New CEO faces test as estimates slide - Investing.com India
Certara, Inc.Common Stock (NQ: CERT - FinancialContent
Certara, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CERT) 2026-02-26 - Seeking Alpha
Certara (NASDAQ:CERT) Issues FY 2026 Earnings Guidance - MarketBeat
Certara, Inc. (CERT) Q4 Earnings Lag Estimates - Yahoo Finance
Certara, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Certara Q4 Adjusted Earnings Fall, Revenue Rises; 2026 Outlook Set - marketscreener.com
Certara, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):